As part of our ongoing service improvement program, the Infection & Immunity laboratory plan to switch from the current Biomérieux CMV IgM and IgG assays performed on the Vidas platform, to the more automated Abbott Architect assays. A comparison of the Architect versus Biomérieux assays has shown that the performance of both assays is very similar in terms of both sensitivity and specificity. The improvement to the service that is anticipated is that you will notice reduced result turnaround times.
This this change will be implemented by the end of April 2017.
If you wish to discuss the above, please do not hesitate to contact us.